Stock Events

Stock Events

Humacyte 

$0.000900
531
+$0.00+0% Tuesday 19:59
+$0.00+0%Tuesday 20:00After hours

Statistics

Day High
0.0039
Day Low
0.0009
52W High
0.0039
52W Low
0.0009
Volume
258,659
Avg. Volume
-
Mkt Cap
250,018.29
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.25
-0.07
0.1
0.28
Expected EPS
-0.09128
Actual EPS
N/A

Financials

-2,003.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.04MRevenue
-40.83MNet Income

Analyst Ratings

5.11Average Price Target
The highest estimate is 25.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
71%
Hold
29%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HUMAW. It's not an investment recommendation.
Bitcoin
101
BTC.CRYPTO
Quanterix
93
QTRX
NVIDIA
89
NVDA
Amazon
79
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mimedx Group
MDXG
Mkt Cap655.92M
MiMedx Group, Inc. specializes in regenerative biomaterials, a field closely related to Humacyte's focus on regenerative medical technologies.
Precigen
PGEN
Mkt Cap2.49B
Precigen, Inc. operates in the synthetic biology sector, developing therapies that could compete with Humacyte's tissue-engineered products.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies, competing in the broader regenerative medicine space.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics AG focuses on gene editing, a technology that could rival Humacyte's approach to regenerative medicine.
Vericel
VCEL
Mkt Cap2.1B
Vericel Corporation produces autologous cell therapies for repair and regeneration of human tissues, directly competing with Humacyte's products.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, potentially competing in the regenerative medicine market.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine, Inc. is a leading gene editing company, which competes in the innovative therapeutic space alongside Humacyte.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics, Inc. is another gene editing company, representing competition in the development of novel regenerative therapies.

About

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Show more...
CEO
Laura E. Niklason
Employees
184
Country
United States
ISIN
US44486Q1114

Listings

XNAS
US
HUMAW
XNAS
US
HUMA
BOATS
BOATS
HUMA.BOATS

0 Comments

Share your thoughts

FAQ

What is Humacyte stock price today?▼
The current price of HUMAW is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Humacyte stock price performance more closely on the chart.
What is Humacyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Humacyte stocks are traded under the ticker HUMAW.
What is Humacyte market cap?▼
Today Humacyte has the market capitalization of 250,018.29
When is the next Humacyte earnings date?▼
Humacyte is going to release the next earnings report on November 06, 2026.
What were Humacyte earnings last quarter?▼
HUMAW earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.11 USD resulting in a -41.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Humacyte revenue for the last year?▼
Humacyte revenue for the last year amounts to 2.04M USD.
What is Humacyte net income for the last year?▼
HUMAW net income for the last year is -40.83M USD.
How many employees does Humacyte have?▼
As of September 01, 2026, the company has 184 employees.
In which sector is Humacyte located?▼
Humacyte operates in the Health & Wellness sector.
When did Humacyte complete a stock split?▼
Humacyte has not had any recent stock splits.
Where is Humacyte headquartered?▼
Humacyte is headquartered in DURHAM, United States.